The Breast Cancer Drug the FDA Said Yes to After Experts Said No

The results were striking. Patients who switched to camizestrant plus a CDK4/6 inhibitor (a class of drugs already standard in breast cancer care) had a median progression-free survival of 16 months, compared to just 9.2 months for those who stayed on their original therapy. That's a 56% reduction in the risk of disease progression or death.

At the two-year mark, the gap was even more dramatic: 29.7% of camizestrant patients remained progression-free versus just 5.4% in the control group.

So Why Did the Advisory Committee Say No?

With numbers like those, you'd think approval would be a slam dunk. The advisory panel disagreed, and their concerns were legitimate.

The biggest issue was overall survival data. The trial showed patients lived longer without their cancer worsening, but the committee wanted proof that they actually lived longer, period. At the time of the vote, survival data was still immature. The panel also raised questions about the study design itself: was switching treatment based on a blood test, before scans showed any worsening, truly the right move? And was there a clear quality-of-life benefit?

These aren't trivial objections. In oncology, progression-free survival doesn't always translate into longer life. Sometimes it just delays the inevitable without changing the final outcome.

The FDA's Calculated Bet

The FDA clearly weighed all of this and came to a different conclusion. By granting accelerated approval, the agency essentially said: "The data is promising enough to let patients access this now, but we're going to need confirmatory evidence later."

Accelerated approval is the FDA's version of a conditional yes. AstraZeneca gets to sell the drug, but the company must run additional studies to prove the benefit holds up over time. If those studies disappoint, the FDA can yank the approval.

The approved label is also narrower than what AstraZeneca originally wanted. Camizestrant is approved specifically for HR-positive, HER2-negative advanced breast cancer patients who develop an ESR1 mutation while on aromatase inhibitor and CDK4/6 inhibitor therapy. That's a biomarker-defined subset, not all comers. The FDA also approved Guardant's Guardant360 CDx as the companion diagnostic test to identify eligible patients.

A Precedent That Could Reshape Drug Approvals

FDA overrides of negative advisory votes are rare, but not unprecedented. The agency approved aducanumab (the Alzheimer's drug Aduhelm) in 2021 after a nearly unanimous negative vote, sparking one of the biggest controversies in recent FDA history. Panel members resigned in protest; insurers refused to pay.

Before that, there was eteplirsen for Duchenne muscular dystrophy in 2016, another approval that divided the medical community. So while uncommon, it happens more than people think.

But each new case emboldens the next sponsor. If you're a biotech company sitting on borderline clinical data and a negative committee vote, camizestrant's approval gives you a playbook: argue for unmet need, point to a specific patient population, and hope the FDA sees the forest through the trees.

The Competitive Race for Oral SERDs

Camizestrant isn't alone in this space. Eli Lilly's imlunestrant received FDA approval roughly a year earlier, in September 2025, for a similar ESR1-mutant breast cancer population. That gives Lilly a head start in commercial adoption.

The two drugs are carving out slightly different niches. Imlunestrant has first-mover advantage and broader early traction. Camizestrant's calling card is the SERENA-6 data, which represents a more differentiated "molecular switch" strategy: detect the mutation early, change treatment proactively.

Fulvestrant, the injectable SERD that's been the workhorse for years, is likely to lose ground as oral options expand. Nobody wants a monthly injection when a daily pill is on the table.

The Money Question

AstraZeneca has publicly stated that camizestrant could eventually exceed $5 billion in annual sales. Wall Street is considerably more skeptical; analyst estimates peg 2032 sales at around $2.3 billion. The gap tells you everything about how much of the drug's commercial potential depends on label expansion beyond the current narrow indication.

The approved market today is constrained by biomarker testing requirements and the specific treatment setting. The real upside, analysts say, would come from moving camizestrant into early-stage breast cancer, where the patient population is vastly larger. That's still years away.

For now, the approval is a clear win for AstraZeneca, especially given the advisory committee rejection. It validates a new treatment paradigm built around blood-based mutation detection, and it gives patients with a specific, hard-to-treat cancer subtype an oral option that meaningfully delays disease progression.

Whether the FDA's bet pays off depends on confirmatory data that hasn't arrived yet. The clock is ticking.